Following on from a dose-escalation assessment in their phase-1 trial [38], patients with unresectable or metastatic NSCLC with a KRAS G12C mutation were treated twice daily with a 600 mg dose of oral adagrasib, with a primary endpoint of objective response [34]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.